Evidence map›Paper›PMID 33219442›Full record

Observational studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2021

Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry.

Marc Figueras-Roca, Alba Parrado-Carrillo, Vuong Nguyen, Ricardo P Casaroli-Marano, Aina Moll-Udina, Mark C Gillies, Daniel Barthelmes, Javier Zarranz-Ventura

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Application of big data in ophthalmology.Taiwan journal of ophthalmology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Marc Figueras-RocaInstitut Clínic d'Oftalmologia (ICOF), Hospital Clínic de Barcelona, C/Sabino de Arana 1, 08028, Barcelona, Spain. mafiguer@clinic.cat.ORCID http://orcid.org/0000-0002-0548-0539
Alba Parrado-CarrilloInstitut Clínic d'Oftalmologia (ICOF), Hospital Clínic de Barcelona, C/Sabino de Arana 1, 08028, Barcelona, Spain.
Vuong NguyenMacular Research Group, Save Sight Institute, University of Sydney, Sydney, Australia.
Ricardo P Casaroli-MaranoInstitut Clínic d'Oftalmologia (ICOF), Hospital Clínic de Barcelona, C/Sabino de Arana 1, 08028, Barcelona, Spain.
Aina Moll-UdinaInstitut Clínic d'Oftalmologia (ICOF), Hospital Clínic de Barcelona, C/Sabino de Arana 1, 08028, Barcelona, Spain.
Mark C GilliesMacular Research Group, Save Sight Institute, University of Sydney, Sydney, Australia.
Daniel BarthelmesMacular Research Group, Save Sight Institute, University of Sydney, Sydney, Australia.
Javier Zarranz-VenturaInstitut Clínic d'Oftalmologia (ICOF), Hospital Clínic de Barcelona, C/Sabino de Arana 1, 08028, Barcelona, Spain.
Hospital Clínic de Barcelona · ESThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the outcomes of two different antivascular endothelial growth factor treatment regimens for treatment-naive eyes with neovascular age-related macular degeneration in routine clinical care at 12 and 24 months in Spain.

methodsObservational study using the Fight Retinal Blindness (FRB) outcomes registry platform. Eyes were treated with fixed bimonthly (FB) aflibercept group at one center and a treat-and-extend (TAE) regimen using either aflibercept or ranibizumab at the other center.

resultsWe included 192 eyes. Of these, 160 eyes (83%) completed 12 months (86 TAE and 74 FB) and 79 (41%) completed 24 months (46 for TAE and 33 for FB) of follow-up. No statistically significant differences (p > 0.05) were found regarding mean visual acuity (VA, logMAR letters) at baseline (12 month cohort TAE 59.6 vs FB 57.9; 24 month cohort TAE 61.7 vs FB 62.6), final mean VA (12 month cohort TAE 61.1 vs FB 63.0; 24 month cohort TAE 64.8 vs FB 66.4), and median number of injections (12 months TAE 7 vs FB 7; 24 months TAE 11 vs FB 12). However, the distribution of injection frequencies for the TAE group was larger, with 35% of TAE eyes receiving ≤ 6 injections at 12 months compared with only 19% of FB eyes (p = 0.024).

conclusionSimilar VA results were observed with TAE and FB regimens, with no differences in the median number of injections. However, the TAE approach seemed to deliver a wider distribution of injection frequencies due to its individualized approach, which may help reduce the burden of injections in some eyes.

Indexed as

Macular DegenerationWet Macular DegenerationAngiogenesis InhibitorsBlindnessChild, PreschoolHumansInfantIntravitreal InjectionsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRegistriesTreatment OutcomeAngiogenesis InhibitorsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsBenchmark standardElectronic medical recordFixed bimonthlyNaiveNeovascular age–related macular degenerationTreat and extend

Identifiers

PMID33219442
OpenAlexW3100869523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.